Checkpoint immunotherapy has yielded meaningful responses across many cancers but
has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7 …

Abstract B7-H3 (CD276) is an immune checkpoint overexpressed in prostate cancer with
minimal expression in normal tissues and associated with poor prognosis, making it an …

Background: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules,
has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism …

Background Prostate cancer spans a broad spectrum from indolent to deadly disease. In the
management of prostate cancer, diagnostic biopsy specimens are important sources of data …

Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer
progression. This immune checkpoint molecule is selectively expressed in both tumor cells …

Targeting the anti-tumor immune response via the B7 family of immune-regulatory
checkpoint proteins has revolutionized cancer treatment and resulted in punctuated …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Immune checkpoint inhibitors (ICIs) for programmed death-1 (PD-1) and programmed cell
death-ligand 1 (PD-L1) have become preferred treatment strategies for several advanced …

Immune checkpoint molecules play critical roles in regulating the anti-tumor immune
response, and tumor cells often exploit these pathways to inhibit and evade the immune …

Background B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed in
prostate cancers (PCs). Understanding its longitudinal expression at emergence of …